PubHawk
BMC Med March 2025 PMID 40038638

Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis.

Zahra Goudarzi, Farhad Lotfi, Rahil Sadat Shahtaheri, Nasrin Moradi, Mohsen Taghizadeh, Khosro Keshavarz

Full text PDF Download social card

Mentions

3
Peak: 3 in Mar 2025
across 2 sources since Mar 2025

Extended reach

4,658
potential audience

Total likes

6

Video views

149

Mentions per month

Mar 2025

All 3 dated mentions so far are from Mar 2025.

Where it's discussed

  • YouTube2 videos
  • X / Twitter1 posts

AI synopsis

What people are saying

The overall tone and content reveal that the group recognizes the study's importance, with mentions of cost savings and treatment efficacy, such as referring to CBD as a 'cost-effective option' and discussing the 5-year budget impact, which highlights their engagement with both its clinical and economic implications.

AgreementModerate agreement

Most discussions acknowledge the study's positive findings regarding CBD's cost-effectiveness for LGS, indicating general agreement with the publication's conclusions.

InterestModerate interest

Participants show moderate curiosity, referencing specific data points like the $6,573 per QALY and the 77% probability, suggesting a fair level of engagement drawn from the article’s detailed analysis.

EngagementModerate engagement

Comments often delve into the implications of the study, with some discussing the potential for CBD to become a standard treatment, reflecting a willingness to consider broader impacts.

ImpactModerate impact

The discussions highlight that the study could influence treatment decisions and healthcare policies, emphasizing its significance for patient care and economic considerations.

Abstract in brief

  • Lennox-Gastaut syndrome (LGS) significantly impacts quality of life, and this study analyzed the cost-effectiveness of using cannabidiol (CBD) for treatment compared to usual care.
  • A Markov model was employed to assess costs over a lifetime and a 5-year budget impact, revealing that CBD is cost-effective at $6,573 per quality-adjusted life-year (QALY) gained with a 77% probability of being a valuable treatment option.
  • Overall, the introduction of CBD could increase healthcare costs by approximately $3.46 million over the next five years, suggesting it is a sustainable option for LGS patients, pending further real-world validation.
Read the full abstract

Top posts

Most liked on X and Bluesky
Greenthumb_one
@Greenthumb_one · X

Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis https://t.co/Hujzi68YlK

Mar 7, 2025 · 1 like · 4,510 followers View post →

All mentions

Greenthumb_one
@Greenthumb_one · X

Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis https://t.co/Hujzi68YlK

Mar 7, 2025 · 1 like · 4,510 followers View post →